AU · rank #7 · 2026-07-23
GH
NASDAQ · $20.67B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 1.324 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.10 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 2 |
| Insider signal (90d) $78,456 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $171.08 | +13.5% |
| Momentum acceleration 3-month minus 12-month momentum. | +11.63% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.70 |
| Gross margin TTM | +64.9% |
| 52w high | $174.08 |
| Market cap (USD) | $20.67B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Guardant Health (GH) develops liquid biopsy oncology diagnostics, biopharma data services, and the Shield blood-based colorectal cancer screening franchise, with Q1 2026 revenue up 48% y/y and Shield driving the fastest growth.
Rationale
The quant setup looks valid because analyst estimates and targets are moving up, upside remains ~13.5%, sentiment is strong (4.7/5 rating), and the fundamental print showed accelerating revenue, expanding margins, and management raising 2026 guidance.
Material risks
- 1Shield’s adoption still depends on reimbursement and guideline support, so any delay or weakening in Medicare/ACS-related coverage could slow the main growth engine.
- 2GH remains loss-making with meaningful cash burn, so if execution slips on margin expansion or volume growth, the path to cash-flow breakeven could stretch and pressure valuation.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.